Great Novel Therapeutics Biotech & Medicals Corporation
Update：2026/03/10
Industries
Main Industry
Biotechnology
Main Product/Service
GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.
Founded Year
2013
Unified Business No.
54179426
Status
Active
Number of Employees
10
Total Paid-in
Capital
437,062,350 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2021)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Great Novel Therapeutics Biotech and Medicals Corporation (GNTbm) focuses on innovative oral new drug development for the treatment of advanced and refractory cancers. GNTbm is devoted to cancer immunotherapy, ranging from epigenetic modulators, tumor mic
